Abstract
THE indications for specific antimicrobial therapy for tuberculosis have undergone many changes since the early part of the past decade. This has led to the current consensus that such therapy should be an integral part of the treatment of all forms of active tuberculosis. More recently efforts have been made to broaden the indications further to include persons who have no evidence of tuberculosis other than positive tuberculin reactions and persons who are at special risk for the development of tuberculosis but who are nonreactors to tuberculin. Perhaps a semantic clarification might be useful at this point: at a panel . . .

This publication has 1 reference indexed in Scilit: